The new drugs domestically approved in the first quarter
New drugs approved in this first quarter appear to be outstanding.
According to the present condition of pharmaceutical approvals from the Ministry of Health and Welfare, starting with the Novartis Korea’s Zykadia(generic name: ceritinib) on January, each of the Ildong Pharmaceutical’s Belviq(ge...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
